Cordis公司新型外周支架系统即将在欧洲上市

 
一种新型气球扩张支架叫做Palmaz Blue，极大的方便了医生，因为它的力量增强，不透辐射，体积较小，柔软性增强，输送方便。

这种新型支架具有L605，一种钨增强的钴合金，比不锈钢的强度更大，使用的金属更少。这种支架用于治疗主动脉弓以下的外周血管动脉粥样硬化病变，还可以用于治疗胆道恶性肿瘤的姑息性治疗。

在全球范围内，大约6千万人患外周血管疾病（PVD），包括糖尿病、肥胖、吸烟、高血压、高胆固醇或者有冠心病家族史的患者。这种疾病是由脂肪物质蓄积或者斑块导致的，可以沉积黏附在血管内层。同样，每年成千上万的患者遭受胆管堵塞的致命威胁。胆管支架常常用于扩张堵塞，这样液体可以被运算到各种器官。例如肝脏、胆囊和小肠。

Palmaz Blue支架采用密闭元件设计，锥形放射型拱，优化的支架和双Omega铰链，具有最佳的疲劳寿命，最大的放射力量，最小的体积。Palmaz Blue支架是Cordis Endovascular公司的产品。

Cordis Endovascular公司总经理Jack Springer说：“随着Palmaz Blue支架在欧洲投放市场，我们正在建立令人自豪的遗产，那是在1987年就投放市场的第一代Palmaz支架，以及超过15年的临床上优越的表现。”
 
New Peripheral Stent System
 
A new balloon-expandable stent, called Palmaz Blue, is designed to provide doctors with increased strength, radiopacity, low profiles, and superior flexibility and deliverability.

The new stent features L605, a cobalt alloy enhanced with tungsten, which is stronger than stainless steel and uses less metal. The stent is to be used in the treatment of atherosclerotic lesions in peripheral arteries below the aortic arch as well as in the palliative treatment of malignant neoplasms in the biliary duct.

Worldwide, around 60 million people have peripheral vascular disease (PVD), including those who are diabetic, obese, who smoke, have high blood pressure, have high cholesterol, or have a family history of coronary artery disease. This disease is caused by a build-up of fatty substances or plaques, which collect and adhere to the linings of blood vessels. Also, each year, thousands of patients are threatened by life-threatening blockages in the bile ducts. A biliary stent is often used to open the blockages so that fluids may continue to be transported to various organs such as the liver, gallbladder, and small intestines.

The Palmaz Blue stent features a closed cell design, tapered radial arcs, optimized struts and double Omega hinges that are designed to optimize fatigue life, maximize radial strength, and minimize foreshortening. The Palmaz Blue stent is the product of Cordis Endovascular (Warren, NJ, USA).

“With the European Launch of the Palmaz Blue stent, we are building on a proud legacy which began with the first Palmaz stent introduced in 1987 and more than 15 years of clinical history and long-term performance,” remarked Jack Springer, general manager, Cordis Endovascular.